JP6240155B2 - 経口ワクチン投与のための改善アジュバント系 - Google Patents

経口ワクチン投与のための改善アジュバント系 Download PDF

Info

Publication number
JP6240155B2
JP6240155B2 JP2015504545A JP2015504545A JP6240155B2 JP 6240155 B2 JP6240155 B2 JP 6240155B2 JP 2015504545 A JP2015504545 A JP 2015504545A JP 2015504545 A JP2015504545 A JP 2015504545A JP 6240155 B2 JP6240155 B2 JP 6240155B2
Authority
JP
Japan
Prior art keywords
adjuvant
antigen
aluminum
ctl
eudragit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015504545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512441A5 (enExample
JP2015512441A (ja
Inventor
モアフィールド，ギャリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VAXFORM LLC
Original Assignee
VAXFORM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VAXFORM LLC filed Critical VAXFORM LLC
Publication of JP2015512441A publication Critical patent/JP2015512441A/ja
Publication of JP2015512441A5 publication Critical patent/JP2015512441A5/ja
Application granted granted Critical
Publication of JP6240155B2 publication Critical patent/JP6240155B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2015504545A 2012-04-04 2013-04-03 経口ワクチン投与のための改善アジュバント系 Expired - Fee Related JP6240155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261686372P 2012-04-04 2012-04-04
US61/686,372 2012-04-04
PCT/US2013/000102 WO2013151595A1 (en) 2012-04-04 2013-04-03 Improved adjuvant system for oral vaccine adminstration

Publications (3)

Publication Number Publication Date
JP2015512441A JP2015512441A (ja) 2015-04-27
JP2015512441A5 JP2015512441A5 (enExample) 2015-09-17
JP6240155B2 true JP6240155B2 (ja) 2017-11-29

Family

ID=49300897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015504545A Expired - Fee Related JP6240155B2 (ja) 2012-04-04 2013-04-03 経口ワクチン投与のための改善アジュバント系

Country Status (10)

Country Link
US (3) US20150079130A1 (enExample)
EP (2) EP3549605A1 (enExample)
JP (1) JP6240155B2 (enExample)
KR (1) KR101867428B1 (enExample)
AU (1) AU2013243971B2 (enExample)
CA (1) CA2903313C (enExample)
DK (1) DK2833914T3 (enExample)
IL (1) IL234937B (enExample)
MX (1) MX364946B (enExample)
WO (1) WO2013151595A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3107568B1 (en) * 2014-02-20 2024-03-27 Vaxart, Inc. Formulations for small intestinal delivery
WO2015192216A1 (en) * 2014-06-20 2015-12-23 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
KR102678401B1 (ko) 2015-06-12 2024-06-26 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
CA3016860A1 (en) * 2016-03-07 2017-09-14 Glaxosmithkline Biologicals Sa Drug delivery particles
CA3097058A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
KR102369740B1 (ko) 2020-09-21 2022-03-02 부경대학교 산학협력단 자궁경부암 조기진단을 위한 모바일 질확대경 장치
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
WO1998035562A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US20030162955A1 (en) * 1998-03-17 2003-08-28 Lionel Chalus Isolated mammalian membrane protein genes; related reagents
ES2260916T3 (es) * 1998-07-08 2006-11-01 Kirin-Amgen, Inc. Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica.
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
WO2004018698A2 (en) * 2002-08-20 2004-03-04 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2004073652A2 (en) * 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
EP2464341B1 (en) * 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB0919690D0 (en) * 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions

Also Published As

Publication number Publication date
AU2013243971B2 (en) 2017-01-05
IL234937B (en) 2021-10-31
MX364946B (es) 2019-05-15
US20190105389A1 (en) 2019-04-11
CA2903313A1 (en) 2013-10-10
EP2833914A4 (en) 2016-03-30
MX2014011806A (es) 2015-06-03
IL234937A0 (en) 2014-12-31
US20210052725A1 (en) 2021-02-25
EP2833914A1 (en) 2015-02-11
CA2903313C (en) 2019-10-22
WO2013151595A1 (en) 2013-10-10
EP2833914B1 (en) 2019-01-16
US20150079130A1 (en) 2015-03-19
KR20150002755A (ko) 2015-01-07
AU2013243971A1 (en) 2014-10-02
JP2015512441A (ja) 2015-04-27
EP3549605A1 (en) 2019-10-09
KR101867428B1 (ko) 2018-07-19
DK2833914T3 (en) 2019-03-11

Similar Documents

Publication Publication Date Title
US20210052725A1 (en) Adjuvant system for oral vaccine administration
US20070237826A1 (en) Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
KR101960102B1 (ko) 비강내 전달을 위한 방법 및 조성물
CN108697778A (zh) 病原体疫苗及其生产和使用方法
US12318436B2 (en) Composition and method for spray drying an adjuvant vaccine emulsion
CN107625958A (zh) 热稳定性疫苗组合物及其制备方法
WO2010050578A1 (ja) カチオン性ナノゲルを用いる粘膜ワクチン
Hendy et al. Nano/microparticle Formulations for Universal Influenza Vaccines: Nano/microparticle Formulations for Universal Influenza Vaccines
Manju et al. Nanovaccines to combat drug resistance: The next-generation immunisation
Prajapati et al. In-Vitro And In-Vivo Assessment of Antigen-Encapsulated Dextran Nanoparticles
US9216215B2 (en) Adjuvant system for vaccine adjuvant
US20250057945A1 (en) Vaccine adjuvant agent containing polyacrylic acid polymer and use of same
US20200405849A1 (en) Vaccine system for vaccine adjuvant
Ohta Cholesteryl Pullulan Nanoparticles-Encapsulated TNF-a: An Effective Mucosal Vaccine Adjuvant Against
Valiveti Polymeric Nanovaccine Delivery System for Influenza Vaccine
Hassett Ultra stable glassy state vaccines containing adjuvants
Hassett et al. Formulation Approaches and Strategies for Vaccines and Adjuvants
Lu EVALUATION OF ALPHA-D-GLUCAN NANOPARTICLE AS A VACCINE ADJUVANT
Gregory Investigating the use of gold nanoparticles in vaccine delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171102

R150 Certificate of patent or registration of utility model

Ref document number: 6240155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees